About this item:

30 Views | 56 Downloads

Author Notes:

Correspondence to Cassie Mitchell, cassie.mitchell@bme.gatech.edu

Author contributions: SH: study design, acquisition of data, completion of statistical analysis, and drafting of the initial manuscript; IO: design of statistical analysis, interpretation of results, and critical revision of the manuscript for important intellectual content; CM: study concept and design, acquisition of data, overall study supervision, interpretation of results, revision of the initial draft, and writing of the final manuscript.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Subjects:

Research Funding:

Funding provided by USA National Institute of Health grants NS081426 and NS069616 to CM.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Clinical Neurology
  • Neurosciences
  • Neurosciences & Neurology
  • motor neuron disease
  • premobidity
  • comorbidity
  • preexisting condition
  • epidemiology
  • BODY-MASS INDEX
  • PHYSICAL-ACTIVITY
  • SURVIVAL
  • RISK
  • DYSLIPIDEMIA
  • PROGRESSION
  • ALS

Antecedent Disease and Amyotrophic Lateral Sclerosis: What Is Protecting Whom?

Tools:

Journal Title:

Frontiers in Neurology

Volume:

Volume 7, Number MAR

Publisher:

, Pages 47-47

Type of Work:

Article | Final Publisher PDF

Abstract:

Multiple studies have shown that antecedent diseases are less prevalent in amyotrophic lateral sclerosis (ALS) patients than the general age-matched population, which suggests possible neuroprotection. Antecedent disease could be protective against ALS or, conversely, the asymptomatic early physiological underpinnings of ALS could be protective against other antecedent disease. Elucidating the impact of antecedent disease on ALS is critical for assessing diagnostic risk factors, prognostic outcomes, and intervention timing. The objective of this study was to examine the relationship between antecedent conditions and ALS onset age and disease duration (i.e. survival). Medical history surveys for 1439 Emory ALS Clinic patients (Atlanta, GA, USA) were assessed for antecedent hypertension, hyperlipidemia, diabetes, obesity, asthma, arthritis, chronic obstructive pulmonary disease (COPD), thyroid, kidney, liver, and other non-ALS neurological diseases. The ALS onset age and disease duration are compared between the antecedent and non-antecedent populations using chi square, Kaplan-Meier, and ordinal logistic regression. When controlled for confounders, antecedent hypertension (high blood pressure), hyperlipidemia (high cholesterol), arthritis, COPD, thyroid disease, and non-ALS neurological disease are found to be statistically associated with a delayed ALS onset age, whereas antecedent obesity [body mass index (BMI) > 30] was correlated to earlier ALS onset age. With the potential exceptions of liver disease and diabetes (the latter without other common comorbid conditions), antecedent disease is associated with overall shorter ALS disease duration. The unique potential relationship between antecedent liver disease and longer ALS disease duration warrants further investigation, especially given liver disease was found to be a factor of 4-7 times less prevalent in ALS. Notably, most conditions associated with delayed ALS onset are also associated with shorter disease duration. Pathological homeostatic instability exacerbated by hypervigilant regulation (over-zealous homeostatic regulation due to too high regulatory feedback gains) is a viable hypothesis for explaining the early-life protection against antecedent disease and the overall lower antecedent disease prevalence in ALS patients; the later ALS onset age in patients with antecedent disease; and the inverse relationship between ALS onset age and disease duration.

Copyright information:

© 2016 Hollinger, Okosun and Mitchell.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote